Replies to post #73654 on Biotech Values

[DewDiligence]

Re: R7128 phase-2 trial design

Isn’t it odd that the actual design differs in so many respects from the intended design described in the 1/12/09 PR? I’m not sure whether having three trials arms with the 90mcg “half” Pegasys dose (including one arm that tests 90mcg Pegasys with the extra-high 1500mg BID dose of R7128) should be viewed as bullish or bearish for R7128.

[DewDiligence]

ghmm et al re VRUS: Mystery solved regarding the R7128 dosing change: there wasn’t one and the clinicaltials.gov entry was simply mistaken!

In the phase-2b trial, the trial arms listed in yesterday’s PR (#msg-37306882) are the same as the trial arms in VRUS’ Jan 2009 PR (#msg-34746768).